Evidence map›Paper›PMID 25122801›Full record

ArticleJournal of virology2014

Combined alphavirus replicon particle vaccine induces durable and cross-protective immune responses against equine encephalitis viruses.

Douglas S Reed, Pamela J Glass, Russell R Bakken, James F Barth, Cathleen M Lind, Luis da Silva, Mary Kate Hart, Jonathan Rayner, Kim Alterson, Max Custer and 5 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 58 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Development ofEmerging microbes & infections · 2025
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Douglas S ReedCenter for Aerobiological Sciences, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland, USA dsreed@pitt.edu.
Pamela J GlassVirology Division, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland, USA.
Russell R BakkenVirology Division, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland, USA.
James F BarthVirology Division, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland, USA.
Cathleen M LindVirology Division, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland, USA.
Luis da SilvaCenter for Aerobiological Sciences, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland, USA.
Mary Kate HartVirology Division, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland, USA.
Jonathan RaynerAlphaVax, Inc., Research Triangle Park, North Carolina, USA.
Kim AltersonAlphaVax, Inc., Research Triangle Park, North Carolina, USA.
Max CusterAlphaVax, Inc., Research Triangle Park, North Carolina, USA.
Jeanne DudekAlphaVax, Inc., Research Triangle Park, North Carolina, USA.
Gary OwensAlphaVax, Inc., Research Triangle Park, North Carolina, USA.
Kurt I KamrudAlphaVax, Inc., Research Triangle Park, North Carolina, USA.
Michael D ParkerVirology Division, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland, USA.
Jonathan SmithAlphaVax, Inc., Research Triangle Park, North Carolina, USA.
United States Army Medical Research Institute of Infectious Diseases · USAlphaVax (United States) · US

Funding

PHS HHS U01 A|056438-04
6 · The paper itself

Abstract

Alphavirus replicons were evaluated as potential vaccine candidates for Venezuelan equine encephalitis virus (VEEV), western equine encephalitis virus (WEEV), or eastern equine encephalitis virus (EEEV) when given individually or in combination (V/W/E) to mice or cynomolgus macaques. Individual replicon vaccines or the combination V/W/E replicon vaccine elicited strong neutralizing antibodies in mice to their respective alphavirus. Protection from either subcutaneous or aerosol challenge with VEEV, WEEV, or EEEV was demonstrated out to 12 months after vaccination in mice. Individual replicon vaccines or the combination V/W/E replicon vaccine elicited strong neutralizing antibodies in macaques and demonstrated good protection against aerosol challenge with an epizootic VEEV-IAB virus, Trinidad donkey. Similarly, the EEEV replicon and V/W/E combination vaccine elicited neutralizing antibodies against EEEV and protected against aerosol exposure to a North American variety of EEEV. Both the WEEV replicon and combination V/W/E vaccination, however, elicited poor neutralizing antibodies to WEEV in macaques, and the protection conferred was not as strong. These results demonstrate that a combination V/W/E vaccine is possible for protection against aerosol challenge and that cross-interference between the vaccines is minimal. Importance: Three related viruses belonging to the genus Alphavirus cause severe encephalitis in humans: Venezuelan equine encephalitis virus (VEEV), western equine encephalitis virus (WEEV), and eastern equine encephalitis virus (EEEV). Normally transmitted by mosquitoes, these viruses can cause disease when inhaled, so there is concern that these viruses could be used as biological weapons. Prior reports have suggested that vaccines for these three viruses might interfere with one another. We have developed a combined vaccine for Venezuelan equine encephalitis, western equine encephalitis, and eastern equine encephalitis expressing the surface proteins of all three viruses. In this report we demonstrate in both mice and macaques that this combined vaccine is safe, generates a strong immune response, and protects against aerosol challenge with the viruses that cause Venezuelan equine encephalitis, western equine encephalitis, and eastern equine encephalitis.

Indexed as

RepliconAlphavirusAnimalsAntibodies, NeutralizingBlotting, WesternChlorocebus aethiopsCricetinaeEncephalitis Virus, Eastern EquineEnzyme-Linked Immunosorbent AssayFemaleFluorescent Antibody TechniqueMacaca fascicularisMaleMiceVero CellsViral VaccinesAntibodies, NeutralizingViral Vaccines

Identifiers

PMID25122801
PMCPMC4178741
OpenAlexW2051827882

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.